University of California Davis, Department of Human Ecology, Davis, CA 95616, United States of America.
University of California Davis, Department of Human Ecology, Davis, CA 95616, United States of America.
Contemp Clin Trials. 2022 Feb;113:106627. doi: 10.1016/j.cct.2021.106627. Epub 2021 Nov 20.
Excess gestational weight gain (EGWG) is associated with multiple pregnancy complications and health risks for birthing people and their infants. Likewise, postpartum weight retention (PPWR), or not losing all pregnancy weight, has long-term health consequences. EGWG among people who enter pregnancy with overweight or obesity have worse obstetric outcomes and increased PPWR compared to women who gain within Institute of Medicine guidelines.
This study protocol describes the details of a blinded, randomized clinical trial of GROWell: Goals for Reaching Optimal Wellness, a mHealth tool designed to improve diet quality among people who enter pregnancy with overweight or obese BMIs to help them achieve appropriate GWG and safe postpartum pregnancy weight loss. Individuals with overweight and obesity will be randomly assigned to an attention control or intervention arm. The intervention group will receive personalized, goal-oriented text messages regarding dietary choices, while the attention control group will receive text messages about healthy pregnancy, labor, delivery, and early infancy. Both groups will complete online surveys at baseline, follow up, 3 and 6 months postpartum.
Currently, 162 subjects have been enrolled. Outcomes associated with GWG and pregnancy are expected in late 2023, while outcomes on postpartum weight retention GROWell adherence are expected in late 2024. The results of this trial will support the use of an evidence-based mHealth tool to be integrated into clinical practice to reduce EGWG and PPWR among pregnant people with overweight and obese BMIs, a resource that is currently lacking.
ClinicalTrials.gov identifier: NCT04449432. Registered on June 26, 2020.
妊娠期间体重增加过多(EGWG)与多种妊娠并发症以及母婴的健康风险相关。同样,产后体重滞留(PPWR),即未能减轻所有妊娠体重,也会对健康造成长期影响。与体重指数(BMI)处于超重或肥胖范围内并遵循医学研究所指南增加体重的女性相比,超重或肥胖人群的 EGWG 会导致更差的产科结局和更高的 PPWR。
本研究方案详细描述了 GROWell(追求最佳健康的目标)的一项盲法、随机临床试验的细节,这是一种移动健康工具,旨在改善超重或肥胖人群的妊娠期间饮食质量,帮助她们实现适当的 GWG 和安全的产后妊娠体重减轻。超重和肥胖个体将被随机分配到关注对照组或干预组。干预组将收到有关饮食选择的个性化、目标导向的短信,而关注对照组将收到有关健康妊娠、分娩、产后和婴儿早期的短信。两组均将在基线、随访、产后 3 个月和 6 个月完成在线调查。
目前,已有 162 名受试者入组。预计在 2023 年底得出与 GWG 和妊娠相关的结果,而关于 GROWell 依从性与产后体重滞留的结果预计在 2024 年底得出。该试验的结果将支持使用循证移动健康工具来整合到临床实践中,以减少超重和肥胖 BMI 孕妇的 EGWG 和 PPWR,目前这方面的资源还很缺乏。
ClinicalTrials.gov 标识符:NCT04449432。于 2020 年 6 月 26 日注册。